Abstract:132 Background: Most recently, there were 3 reports of prospective randomized clinical trials comparing the effects of primary tumor resection (PTR) for multiorgan metastatic colorectal cancer followed by chemotherapy with chemotherapy alone, but the results differed and unconvincing due to the prematurely study termination and research protocol changes. PTR was preferably performed for patients with asymptomatic synchronous unresectable colorectal liver-limited metastases (CRLMs) with conversion therapy purpose, including the CELIM, OLIVIA and our study (J Clin Oncol 2013;31:1931-8). This randomized phase III study investigated the superiority of preoperative chemotherapy prior to PTR for patients with asymptomatic synchronous unresectable CRLMs. Methods: Patients with asymptomatic synchronous unresectable CRLMs were randomly assigned to receive pre-PTR chemotherapy (arm A) or upfront PTR (arm B). Chemotherapy regimens of mFOLFOX6 plus cetuximab, mFOLFOX6 plus bevacizumab or mFOLFOX6 alone were decided according to the RAS genotype. The primary end point was progression-free survival (PFS); secondary end points included overall survival (OS), tumor response, disease control rate (DCR), liver metastases resection rate, surgical complications and chemotherapy toxicity. Results: Between June 2012 and June 2018, a total of 320 patients were randomly assigned to arm A (160 patients) or arm B (160 patients). The cutoff date for survival data was June 2021, the median follow-up time was 36.2 months. Patients were well balanced. For the intention-to-treat population, the median PFS, median OS, and 3-year OS rates were 9.9 months, 28.0 months, and 37.0%, respectively. The median PFS in arm A was significantly improved compared with arm B (10.5 v 9.1 months; hazard ratio [95% CI, 0.60 to 0.95], 0.76; P = 0.013). Patients in arm A also had a significantly better DCR (84.4% v 75.0%; P = 0.037). The median OS was not significantly different (29.4 v 27.2 months; hazard ratio [95% CI, 0.58 to 1.01], 0.77, P = 0.058), and the objective response rates were also not significantly different (53.1% v 45.0%; P = 0.146). The actual resection rate of liver metastases was not significantly different (21.9% v 18.1%; P = 0.402). There were mild morbidities and no 30-day postoperative mortalities in both arms. The rate of complications was not significantly different (37.7% v 30.8%, P = 0.201). The incidence of Clavien–Dindo 3-4 complications also did not reach statistical significance (4.5% v 3.8%, P = 0.759). Overall the observed toxicity was mostly mild. There was no significant difference in the overall incidence of predefined grade 3/4 events (42.2% v 40.4%, P = 0.744). There were no grade 5 events in either arm. Conclusions: For asymptomatic synchronous unresectable CRLMs, Pre-PTR chemotherapy improved the PFS compared with upfront PTR. Clinical trial information: NCT01307878 .

Staged Resection Versus Simultaneous Resection for Conversion Surgery for Initially Unresectable Colorectal Liver Metastasis: A Prospective Cohort Study.

Efficacy of conversion therapy on future liver remnant hypertrophy for initially unresectable colorectal liver metastases: a review of current status and perspectives

Simultaneous versus staged liver resection of synchronous liver metastasis from colorectal cancer

Simultaneous vs. staged resection for synchronous colorectal liver metastases: a metaanalysis

Comparison Between Simultaneous Resection and Staged Resection for Synchronous Colorectal Liver Metastasis: a Meta-analysis

Simultaneous versus staged liver resection of synchronous liver metastasis from colorectal cancer]

Simultaneous versus staged resection for synchronous rectal cancer liver metastasis

Meta-analysis of simultaneous versus staged resection for synchronous colorectal liver metastases.

Timing of Hepatectomy for Resectable Synchronous Colorectal Liver Metastases: for Whom Simultaneous Resection is More Suitable - A Meta-Analysis

Conversion Therapy Combined With Individualized Surgical Treatment Strategy Improves Survival In Patients With Colorectal Cancer Liver Metastases

Simultaneous Liver and Colorectal Resections Are Safe for Synchronous Colorectal Liver Metastases

Preoperative Chemotherapy Prior to Primary Tumor Resection for Asymptomatic Synchronous Unresectable Colorectal Liver-Limited Metastases: A Multicenter Randomized Controlled Trial.

[A Meta-Analysis of the Safety of Simultaneous Versus Staged Resection for Synchronous Liver Metastasis from Colorectal Cancer].

Association of Simultaneous Vs Delayed Resection of Liver Metastasis with Complications and Survival among Adults with Colorectal Cancer

Conversion managment of colorectal cancer with simultaneous unresectable hepatic metastasis

Survival and Prognostic Factors of Colorectal Liver Metastases after Surgical and Nonsurgical Treatment.

Propensity-score matched outcomes of resection of stage IV primary colon cancer with and without simultaneous resection of liver metastases

Impact of Surgical Management for Relapse after Conversion Hepatectomy for Initially Unresectable Colorectal Liver Metastasis: A Retrospective Cohort Study.

Short- and Long-Term Outcomes in Simultaneous Resection of Colorectal Cancer and Liver Metastasis with Minimally Invasive or Open Surgery

Comparison of Sequential, Delayed and Simultaneous Resection Strategies for Synchronous Colorectal Liver Metastases

Optimal Surgical Sequence for Colorectal Cancer Liver Metastases Patients Receiving Colorectal Cancer Resection with Simultaneous Liver Metastasis Resection: A Multicentre Retrospective Propensity Score Matching Study.